aav2介导的实体瘤体内免疫基因治疗。

Sara A Collins, Alexandra Buhles, Martina F Scallan, Patrick T Harrison, Deirdre M O'Hanlon, Gerald C O'Sullivan, Mark Tangney
{"title":"aav2介导的实体瘤体内免疫基因治疗。","authors":"Sara A Collins,&nbsp;Alexandra Buhles,&nbsp;Martina F Scallan,&nbsp;Patrick T Harrison,&nbsp;Deirdre M O'Hanlon,&nbsp;Gerald C O'Sullivan,&nbsp;Mark Tangney","doi":"10.1186/1479-0556-8-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major strategies adopted for cancer gene therapy and seeks to stimulate the immune system to target tumour antigens. In this study, the feasibility of AAV2 mediated immunotherapy of growing tumours was examined, in isolation and combined with anti-angiogenic therapy.</p><p><strong>Methods: </strong>Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM) delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction. Tumour growth and survival was monitored for all animals. Cured animals were re-challenged with tumourigenic doses of the original tumour type. In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.</p><p><strong>Results: </strong>AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an increase in survival in both tumour models. Cured animals were resistant to re-challenge, and induction of T cell mediated anti-tumour responses were demonstrated. Adoptive transfer of splenocytes to naïve animals prevented tumour establishment. Systemic production of Nk4 induced by intra-muscular (IM) delivery of Nk4 significantly reduced subcutaneous tumour growth. However, combination of Nk4 treatment with GM-CSF, B7-1 therapy reduced the efficacy of the immune therapy.</p><p><strong>Conclusions: </strong>Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and provides data on the inter-relationship between tumour vasculature and immune cell recruitment.</p>","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"8 ","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-8-8","citationCount":"10","resultStr":"{\"title\":\"AAV2-mediated in vivo immune gene therapy of solid tumours.\",\"authors\":\"Sara A Collins,&nbsp;Alexandra Buhles,&nbsp;Martina F Scallan,&nbsp;Patrick T Harrison,&nbsp;Deirdre M O'Hanlon,&nbsp;Gerald C O'Sullivan,&nbsp;Mark Tangney\",\"doi\":\"10.1186/1479-0556-8-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major strategies adopted for cancer gene therapy and seeks to stimulate the immune system to target tumour antigens. In this study, the feasibility of AAV2 mediated immunotherapy of growing tumours was examined, in isolation and combined with anti-angiogenic therapy.</p><p><strong>Methods: </strong>Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM) delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction. Tumour growth and survival was monitored for all animals. Cured animals were re-challenged with tumourigenic doses of the original tumour type. In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.</p><p><strong>Results: </strong>AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an increase in survival in both tumour models. Cured animals were resistant to re-challenge, and induction of T cell mediated anti-tumour responses were demonstrated. Adoptive transfer of splenocytes to naïve animals prevented tumour establishment. Systemic production of Nk4 induced by intra-muscular (IM) delivery of Nk4 significantly reduced subcutaneous tumour growth. However, combination of Nk4 treatment with GM-CSF, B7-1 therapy reduced the efficacy of the immune therapy.</p><p><strong>Conclusions: </strong>Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and provides data on the inter-relationship between tumour vasculature and immune cell recruitment.</p>\",\"PeriodicalId\":12596,\"journal\":{\"name\":\"Genetic Vaccines and Therapy\",\"volume\":\"8 \",\"pages\":\"8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/1479-0556-8-8\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetic Vaccines and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1479-0556-8-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic Vaccines and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1479-0556-8-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

摘要

背景:为了释放癌症基因治疗的潜力,已经采用了许多策略,包括通过各种方法传递的广泛的治疗基因。免疫疗法已成为癌症基因治疗的主要策略之一,旨在刺激免疫系统靶向肿瘤抗原。在本研究中,研究了AAV2介导的免疫治疗生长肿瘤的可行性,分离和联合抗血管生成治疗。方法:分别在皮下JBS纤维肉瘤或Lewis肺癌(LLC)肿瘤异种移植物的Balb/C或C57小鼠中,在肿瘤诱导前14天,分别在瘤内给药编码免疫上调细胞因子粒细胞巨噬细胞集落刺激因子(GM-CSF)的AAV2载体和共刺激分子B7-1,单独或联合肌内(IM)给药编码Nk4的AAV2载体。对所有动物的肿瘤生长和存活情况进行监测。治愈的动物用原肿瘤类型的致瘤剂量再次攻击。体内细胞毒性试验用于研究治疗动物细胞介导反应的建立。结果:aav2介导的GM-CSF、B7-1治疗在两种肿瘤模型中均可显著降低肿瘤生长并增加生存期。治愈的动物对再次攻击具有抵抗力,并证明了诱导T细胞介导的抗肿瘤反应。将脾细胞过继移植到naïve动物体内可以防止肿瘤的形成。肌内注射Nk4诱导全身产生Nk4可显著降低皮下肿瘤的生长。然而,Nk4联合GM-CSF、B7-1治疗降低了免疫治疗的效果。结论:总的来说,本研究证明了体内AAV2介导的免疫基因治疗的潜力,并提供了肿瘤血管和免疫细胞募集之间相互关系的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

AAV2-mediated in vivo immune gene therapy of solid tumours.

AAV2-mediated in vivo immune gene therapy of solid tumours.

AAV2-mediated in vivo immune gene therapy of solid tumours.

AAV2-mediated in vivo immune gene therapy of solid tumours.

Background: Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major strategies adopted for cancer gene therapy and seeks to stimulate the immune system to target tumour antigens. In this study, the feasibility of AAV2 mediated immunotherapy of growing tumours was examined, in isolation and combined with anti-angiogenic therapy.

Methods: Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM) delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction. Tumour growth and survival was monitored for all animals. Cured animals were re-challenged with tumourigenic doses of the original tumour type. In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.

Results: AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an increase in survival in both tumour models. Cured animals were resistant to re-challenge, and induction of T cell mediated anti-tumour responses were demonstrated. Adoptive transfer of splenocytes to naïve animals prevented tumour establishment. Systemic production of Nk4 induced by intra-muscular (IM) delivery of Nk4 significantly reduced subcutaneous tumour growth. However, combination of Nk4 treatment with GM-CSF, B7-1 therapy reduced the efficacy of the immune therapy.

Conclusions: Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and provides data on the inter-relationship between tumour vasculature and immune cell recruitment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信